Subtitle:

Pharmaceutical biotechnology: The achievements of 20th century and the expectations in 21th century

Publisher:

Komitet Biotechnologii PAN ; Instytut Chemii Bioorganicznej PAN

Abstract:

Pharmaceutical biotechnology is 60 years old. Its development one can divide into three essential periods. Two of them have proceeded in past century.The first period started during the Second World War with the industrial production of penicillin and was microbiology-based (microbial metabolites as drugs).The second one was genetic engineering-based and started in 1982, when human insulin synthesized in recombinant bacteria was introduced by pharmaceutical industry to health care. The third period began in 2001 with the first descriptions of the human genome, and is genome-based (also proteome-based).Molecular biology with its new areas - genomics, farmacogenomics and proteomics, together with bioinformatics and other sophfisticated tools developedat the end of XX century and introduced (to the pharmaceutical and medicalbiotechnology of the XXI century) very new ideas and new approaches to drugdiscovery and designin. Pharmaceutical biotechnology (as well as pharmaceutical industry as a whole and world biotechnology as a whole) is entering uponthe third phase of its development, a very integrated and globalized one.

Relation:

Biotechnologia, vol.59, 4 (2002)-.

Volume:

59

Issue:

4

Start page:

56

End page:

78

Detailed Resource Type:

Artykuł

Format:

application/pdf

Resource Identifier:

0860-7796 ; oai:rcin.org.pl:137494 ; IChB B-55

Source:

Biblioteka Instytutu Chemii Bioorganicznej PAN

Language:

pol

Language of abstract:

eng

Temporal coverage:

1988-2010

Rights:

Licencja Creative Commons Uznanie autorstwa-Na tych samych warunkach 4.0

Terms of use:

-

Digitizing institution:

Instytut Chemii Bioorganicznej Polskiej Akademii Nauk

Original in:

Instytut Chemii Bioorganicznej Polskiej Akademii Nauk

Projects co-financed by:

Program Operacyjny Polska Cyfrowa, lata 2014-2020, Działanie 2.3 : Cyfrowa dostępność i użyteczność sektora publicznego; środki z Europejskiego Funduszu Rozwoju Regionalnego oraz współfinansowania krajowego z budżetu państwa

Access:

Otwarty